• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 5, 2011

View Archived Issues

Fighting Lung Cancer: Smokers, Former Smokers, Nonsmokers

Lung cancer remains one of the deadliest cancers – it kills more people than breast, prostate and colon cancers combined. And while it is clearly not an equal opportunity killer, it also strikes a depressing number of former smokers – and a surprising number of nonsmokers. Read More

1Q11 Venture Rounds, IPOs: Spring Comes in Like a Lamb

It's officially spring, and we made it past April Fool's Day still intact. News from the Middle East and the Pacific Rim is scary, but the stock market has had its best quarter in a while. So how did it work out for private biotech firms last quarter, and what might lie ahead? (BioWorld Perspectives) Read More

Tranzyme Prices IPO for GI Drug Development

Tranzyme Inc. priced an initial public offering (IPO) to raise $54 million to support its pipeline of drugs for gastrointestinal motility disorders. The offering price of $4 per share is one-third its original target of $11 to $13. Read More

Stock Movers

Read More

Other News To Note

Plexxikon Inc., of Berkeley, Calif., said its acquisition by Daiichi Sankyo Co. Ltd., of Tokyo, was completed. Under the terms of the deal, Plexxikon shareholders will receive $805 million up front, with near-term milestones associated with approval of melanoma drug PLX4032 totaling an additional $130 million. Read More

EASL Roundup

Idera Pharmaceuticals Inc., of Cambridge, Mass., presented data from a four-week Phase I trial of IMO-2125 in combination with ribavirin in treatment-naïve hepatitis C virus genotype 1 patients, which showed that the combination was well tolerated and produced clinically meaningful antiviral activity. The drug at all dose levels induced declines in viral levels at 48 hours after the first dose, and the mean viral load reductions at 48 hours after the first dose was 2.5 log10, 1.3 log10 and 1.6 log10 for the 0.16 mg/kg once-weekly dose, the 0.32 mg/kg once-weekly dose and the 0.16 mg/kg twice-weekly dose, respectively. Read More

Vivus, Orexigen Jump on CV Data, but No Obesity Win Yet

Cardiovascular data presented for obesity candidates Qnexa (phentermine/topiramate) and Contrave (naltrexone/bupropion) at the American College of Cardiology (ACC) meeting in New Orleans might have boosted shares of Vivus Inc. and Orexigen Therapeutics Inc. Monday, but those results are unlikely to ease the path to approval for either drug. Read More

Solicitor General Offers Fed Circuit a 'Magic Microscope'

WASHINGTON – Instead of making all DNA patents vanish or asking judges to pull rabbits out of their hats every time they have to rule on genomic patents, the Department of Justice (DOJ) recommended they use a "magic microscope" as the legal patent test for clarifying when genetic material is a product of nature. Read More

Clinic Roundup

Stealth Peptides Inc., of Boston, reported results of a Phase I study in healthy volunteers of Bendavia, a compound that targets the mitochondrion to treat ischemia reperfusion injury. Volunteers received a single dose of Bendavia administered as an intravenous infusion over an extended period. Bendavia appears to be safe and well tolerated at the dose evaluated, with no serious adverse events reported. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe